Low-Dose Buprenorphine Boosts Ketamine's Anti-Suicide Effects in Depression
A Stanford trial finds combining buprenorphine with ketamine nearly doubles the reduction in suicidal ideation scores over 31 days.
Summary
A randomized trial from Stanford University found that adding low-dose sublingual buprenorphine after a single ketamine infusion significantly enhanced reductions in suicidal ideation among patients with major depressive disorder. Forty-five patients were studied over 31 days. Those receiving buprenorphine saw mean suicidal ideation scores drop by 11.6 points compared to 6.3 points in the placebo group. This matters because ketamine's anti-suicidal effects are known to be short-lived, and no FDA-approved treatment currently exists specifically for suicidal ideation in depression. The combination offers a potentially scalable outpatient approach for a high-risk population, with results published in the American Journal of Psychiatry and presented at the 2026 American Psychiatric Association annual meeting.
Detailed Summary
Suicide remains one of the most urgent and underserved problems in mental health, claiming roughly 50,000 American lives annually. Despite decades of research, no FDA-approved treatment exists specifically targeting suicidal ideation in major depressive disorder. A new Stanford-led randomized trial now offers a promising pharmacological combination that could change that landscape.
The study tested whether low-dose buprenorphine — an opioid partial agonist already approved for pain and addiction — could extend and amplify ketamine's well-documented but short-lived anti-suicidal effects. Forty-five patients with MDD and active suicidal ideation received a single intravenous ketamine infusion, then were randomized to four weeks of sublingual buprenorphine (0.2–0.8 mg/day) or placebo starting 48 hours later.
Results were clinically meaningful. Suicidal ideation scores on the Scale for Suicide Ideation dropped by a mean of 11.6 points in the buprenorphine group versus 6.3 points in placebo over days 1 to 31, with a Glass delta of 0.76 — a moderate-to-large effect size. Mixed-effects modeling confirmed a significant time-by-treatment interaction (P<0.001), suggesting the benefit was sustained and not just an early spike.
The findings are notable for several reasons. The doses used are well below those prescribed for opioid use disorder, reducing addiction liability concerns. The combination is deliverable in outpatient settings, making it potentially scalable. Researchers noted that many suicidal individuals are high-functioning, holding jobs and families, making accessible outpatient options especially critical.
Important caveats apply. The trial was conducted at a single U.S. center with a relatively small sample of 45 completers, predominantly white and female. The average participant age was 37.6, limiting generalizability. Longer-term follow-up data beyond 31 days is lacking. Independent replication in larger, more diverse populations is essential before clinical adoption. Still, this represents a significant step toward a durable, scalable anti-suicide treatment strategy.
Key Findings
- Buprenorphine plus ketamine reduced suicidal ideation scores by 11.6 points vs 6.3 for ketamine alone over 31 days.
- Effect size was moderate-to-large (Glass delta 0.76), suggesting clinically meaningful benefit beyond placebo.
- Low sublingual doses (0.2–0.8 mg/day) were used, minimizing addiction risk compared to standard buprenorphine dosing.
- No FDA-approved treatment currently exists for suicidal ideation in MDD — this combo targets a critical gap.
- The outpatient design makes this approach potentially scalable for high-risk but high-functioning patients.
Methodology
This is a meeting coverage news report summarizing a peer-reviewed randomized controlled trial published in the American Journal of Psychiatry and presented at the 2026 APA annual meeting. MedPage Today is a credible clinical news outlet. The evidence basis is a single-site RCT with 45 completers, which is preliminary but methodologically sound.
Study Limitations
The trial enrolled only 45 completers at a single U.S. center, limiting statistical power and generalizability. The sample was 72% white and 68% female, reducing applicability to broader populations. Follow-up extended only 31 days, leaving durability of effects beyond one month unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.